<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NADOLOL - nadolol tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<a href="http://"></a>Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt 
Withdrawal<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients 
withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt</span> 
discontinuation of such therapy. When discontinuing chronically administered 
nadolol, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should 
be gradually reduced over a period of 1 to 2 weeks and the patient should be 
carefully monitored. If angina markedly worsens or acute coronary insufficiency 
develops, nadolol administration should be reinstituted promptly, at least 
temporarily, and other measures appropriate for the management of unstable 
angina should be taken. Patients should be warned against interruption or 
discontinuation of therapy without the physician's advice. Because coronary 
artery disease is common and may be unrecognized, it may be prudent not to 
discontinue nadolol therapy abruptly even in patients treated only for 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Nadolol is a synthetic nonselective beta-adrenergic receptor blocking agent 
designated chemically as 1-(<span class="Italics">tert</span>-butylamino)-3-[(5,6,7,8-tetrahydro-<span class="Italics">cis</span>-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol. Its 
structural formula is:</p>
<div class="Figure"><img alt="image of Nadolol chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d208918b-a356-4924-91d9-9593981fe0a6&amp;name=Nadolol%20chemical%20structure.jpg"></div>
<p>Nadolol is a white crystalline powder. It is freely soluble in ethanol, 
soluble in hydrochloric acid, slightly soluble in water and in chloroform, and 
very slightly soluble in sodium hydroxide.</p>
<p>Each tablet for oral administration contains 20 mg, 40 mg or 80 mg of 
nadolol, USP and the following inactive ingredients: croscarmellose sodium, 
lactose (anhydrous), magnesium stearate, microcrystalline cellulose, sodium 
lauryl sulfate, and D&amp;C Yellow No. 10 aluminum lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Nadolol is a nonselective beta-adrenergic receptor blocking 
agent. Clinical pharmacology studies have demonstrated beta-blocking activity by 
showing (1) reduction in heart rate and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> at rest and on exercise, 
(2) reduction of systolic and diastolic blood pressure at rest and on exercise, 
(3) inhibition of isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and (4) reduction of reflex 
orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Nadolol specifically competes with beta-adrenergic receptor agonists for 
available beta receptor sites; it inhibits both the beta<span class="Sub">1</span> 
receptors located chiefly in cardiac muscle and the beta<span class="Sub">2</span> 
receptors located chiefly in the bronchial and vascular musculature, inhibiting 
the chronotropic, inotropic, and vasodilator responses to beta-adrenergic 
stimulation proportionately. Nadolol has no intrinsic sympathomimetic activity 
and, unlike some other beta-adrenergic blocking agents, nadolol has little 
direct myocardial depressant activity and does not have an anesthetic-like 
membrane stabilizing action. Animal and human studies show that nadolol slows 
the sinus rate and depresses AV conduction. In dogs, only minimal amounts of 
nadolol were detected in the brain relative to amounts in blood and other organs 
and tissues. Nadolol has low lipophilicity as determined by octanol/water 
partition coefficient, a characteristic of certain beta-blocking agents that has 
been correlated with the limited extent to which these agents cross the 
blood-brain barrier, their low concentration in the brain, and low incidence of 
CNS-related side effects.</p>
<p>In controlled clinical studies, nadolol at doses of 40 to 320 mg/day has been 
shown to decrease both standing and supine blood pressure, the effect persisting 
for approximately 24 hours after dosing.</p>
<p>The mechanism of the antihypertensive effects of beta-adrenergic receptor 
blocking agents has not been established; however, factors that may be involved 
include (1) competitive antagonism of catecholamines at peripheral (non-CNS) 
adrenergic neuron sites (especially cardiac) leading to decreased cardiac 
output, (2) a central effect leading to reduced tonic-sympathetic nerve outflow 
to the periphery, and (3) suppression of renin secretion by blockade of the 
beta-adrenergic receptors responsible for renin release from the kidneys.</p>
<p>While <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial pressure are reduced by nadolol therapy, 
renal hemodynamics are stable, with preservation of renal blood flow and 
glomerular filtration rate.</p>
<p>By blocking catecholamine-induced increases in heart rate, velocity and 
extent of myocardial contraction, and blood pressure, nadolol generally reduces 
the oxygen requirements of the heart at any given level of effort, making it 
useful for many patients in the long-term management of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. On the 
other hand, nadolol can increase oxygen requirements by increasing left 
ventricular fiber length and end diastolic pressure, particularly in patients 
with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p>Although beta-adrenergic receptor blockade is useful in treatment of angina 
and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, there are also situations in which sympathetic stimulation is 
vital. For example, in patients with severely damaged hearts, adequate 
ventricular function may depend on sympathetic drive. Beta-adrenergic blockade 
may worsen <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> by preventing the necessary facilitating effects of 
sympathetic activity on conduction. Beta<span class="Sub">2</span>-adrenergic 
blockade results in passive bronchial constriction by interfering with 
endogenous adrenergic bronchodilator activity in patients subject to 
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and may also interfere with exogenous bronchodilators in such 
patients.</p>
<p>Absorption of nadolol after oral dosing is variable, averaging about 30%. 
Peak serum concentrations of nadolol usually occur in 3 to 4 hours after oral 
administration and the presence of food in the gastrointestinal tract does not 
affect the rate or extent of nadolol absorption. Approximately 30% of the 
nadolol present in serum is reversibly bound to plasma protein.</p>
<p>Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized 
by the liver and is excreted unchanged, principally by the kidneys.</p>
<p>The half-life of therapeutic doses of nadolol is about 20 to 24 hours, 
permitting once daily dosage. Because nadolol is excreted predominantly in the 
urine, its half-life increases in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#section-8">PRECAUTIONS</a> and <a href="#section-11">DOSAGE AND 
ADMINISTRATION</a>). Steady-state serum concentrations of nadolol are attained 
in 6 to 9 days with once daily dosage in persons with normal renal function. 
Because of variable absorption and different individual responsiveness, the 
proper dosage must be determined by titration.</p>
<p>Exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and 
ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> have been reported after abrupt discontinuation of 
therapy with beta-adrenergic blocking agents in patients with coronary artery 
disease. Abrupt withdrawal of these agents in patients without coronary artery 
disease has resulted in transient symptoms, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, 
<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Several mechanisms have been proposed to 
explain these phenomena, among them increased sensitivity to catecholamines 
because of increased numbers of beta receptors.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span><p class="First">Nadolol tablets are indicated for the long-term management of 
patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><p>Nadolol tablets are indicated in the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; 
it may be used alone or in combination with other antihypertensive agents, 
especially thiazide-type diuretics.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Nadolol tablets are contraindicated in bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> and 
greater than first-degree conduction block, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, and overt cardiac 
failure (see <a href="#section-7">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span><p class="First">Sympathetic stimulation may be a vital component supporting 
circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and its 
inhibition by beta-blockade may precipitate more severe failure. Although 
beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, if necessary, 
they can be used with caution in patients with a history of failure who are well 
compensated, usually with digitalis and diuretics. Beta-adrenergic blocking 
agents do not abolish the inotropic action of digitalis on heart muscle.</p>
<p>IN PATIENTS WITHOUT A HISTORY OF <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span>, continued use of 
beta-blockers can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Therefore, at the 
first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the patient should be digitalized and/or 
treated with diuretics, and the response observed closely, or nadolol should be 
discontinued (gradually, if possible).</p>
<a href="http://"></a><a href="http://"></a>Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt 
Withdrawal<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients 
withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt</span> 
discontinuation of such therapy. When discontinuing chronically administered 
nadolol, particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should 
be gradually reduced over a period of 1 to 2 weeks and the patient should be 
carefully monitored. If angina markedly worsens or acute coronary insufficiency 
develops, nadolol administration should be reinstituted promptly, at least 
temporarily, and other measures appropriate for the management of unstable 
angina should be taken. Patients should be warned against interruption or 
discontinuation of therapy without the physician's advice. Because coronary 
artery disease is common and may be unrecognized, it may be prudent not to 
discontinue nadolol therapy abruptly even in patients treated only for 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<a href="http://"></a><a href="http://"></a>Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, 
<span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>)<p>PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT 
RECEIVE BETA-BLOCKERS. Nadolol should be administered with caution since it may 
block bronchodilation produced by endogenous or exogenous catecholamine 
stimulation of beta<span class="Sub">2</span> receptors.</p>
<a href="http://"></a><a href="http://"></a>Major Surgery<p>Because beta-blockade impairs the ability of the heart to respond 
to reflex stimuli and may increase the risks of general anesthesia and surgical 
procedures, resulting in protracted <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or low <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, it has 
generally been suggested that such therapy should be withdrawn several days 
prior to surgery. Recognition of the increased sensitivity to catecholamines of 
patients recently withdrawn from beta-blocker therapy, however, has made this 
recommendation controversial. If possible, beta-blockers should be withdrawn 
well before surgery takes place. In the event of emergency surgery, the 
anesthesiologist should be informed that the patient is on beta-blocker therapy. 
The effects of nadolol can be reversed by administration of beta-receptor 
agonists such as isoproterenol, dopamine, dobutamine, or levarterenol. 
Difficulty in restarting and maintaining the heart beat has also been reported 
with beta-adrenergic receptor blocking agents.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span><p>Beta-adrenergic blockade may prevent the appearance of 
premonitory signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and blood pressure changes) of 
acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This is especially important with labile diabetics. 
Beta-blockade also reduces the release of insulin in response to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; 
therefore, it may be necessary to adjust the dose of antidiabetic drugs.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span><p>Beta-adrenergic blockade may mask certain clinical signs (e.g., 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> 
should be managed carefully to avoid abrupt withdrawal of beta-adrenergic 
blockade which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span><p class="First">Nadolol should be used with caution in patients with impaired 
renal function. (See <a href="#section-11">DOSAGE AND ADMINISTRATION</a>.)</p>
<a href="http://"></a><a href="http://"></a>Information for Patients<p>Patients, especially those with evidence of coronary artery 
insufficiency, should be warned against interruption or discontinuation of 
nadolol therapy without the physician's advice. Although <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> rarely 
occurs in properly selected patients, patients being treated with 
beta-adrenergic blocking agents should be advised to consult the physician at 
the first sign or symptom of impending failure. The patient should also be 
advised of a proper course in the event of an inadvertently missed dose.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>When administered concurrently, the following drugs may interact 
with beta-adrenergic receptor blocking agents:</p>
<p><span>Anesthetics, general:</span> Exaggeration of the 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> induced by general anesthetics (see <a href="#section-7.4">WARNINGS, 
Major Surgery</a>).</p>
<p><span>Antidiabetic drugs (oral agents and 
insulin):</span> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; adjust dosage of antidiabetic 
drug accordingly (see <a href="#section-7.5">WARNINGS, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and 
<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a>).</p>
<p><span>Catecholamine-depleting drugs</span> 
(e.g.,reserpine): Additive effect; monitor closely for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> 
and/or excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (e.g., <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, postural 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).</p>
<a href="http://"></a><a href="http://"></a>Response to Treatment for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span><p>While taking beta-blockers, patients with a history of severe 
<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated 
challenge, either accidental, diagnostic, or therapeutic. Such patients may be 
unresponsive to the usual doses of epinephrine used to treat allergic 
reaction.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>In chronic oral toxicologic studies (1 to 2 years) in mice, rats, 
and dogs, nadolol did not produce any significant toxic effects. In 2 year oral 
carcinogenic studies in rats and mice, nadolol did not produce any neoplastic, 
preneoplastic, or nonneoplastic pathologic lesions. In fertility and general 
reproductive performance studies in rats, nadolol caused no adverse 
effects.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy Category C<p>In animal reproduction studies with nadolol, evidence of 
embryotoxicity and fetotoxicity was found in rabbits, but not in rats or 
hamsters, at doses five to ten times greater (on a mg/kg basis) than the maximum 
indicated human dose. No teratogenic potential was observed in any of these 
species.</p>
<p>There are no adequate and well controlled studies in pregnant women. Nadolol 
should be used during pregnancy only if the potential benefit justifies the 
potential risk to the fetus. Neonates whose mothers are receiving nadolol at 
parturition have exhibited <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and associated 
symptoms.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Nadolol is excreted in human milk. Because of the potential for 
adverse effects in nursing infants, a decision should be made whether to 
discontinue nursing or to discontinue therapy taking into account the importance 
of nadolol to the mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in pediatric patients have not been 
established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most adverse effects have been mild and transient and have rarely 
required withdrawal of therapy.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> with heart rates of less 
than 60 beats per minute occurs commonly, and heart rates below 40 beats per 
minute and/or symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> were seen in about 2 of 100 patients. 
Symptoms of peripheral <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span>, usually of the Raynaud type, have 
occurred in approximately 2 of 100 patients. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and 
rhythm/conduction disturbances have each occurred in about 1 of 100 patients. 
Single instances of first-degree and third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> have been 
reported; intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> is a known effect of beta-blockers (see 
also <a href="#section-6">CONTRAINDICATIONS</a>, <a href="#section-7">WARNINGS</a>, and <a href="#section-8">PRECAUTIONS</a>).</p>
<p><span class="Bold">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> has been 
reported in approximately 2 of 100 patients; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, sedation, and change 
in behavior have each been reported in approximately 6 of 1,000 patients.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> has been reported in 
approximately 1 of 1,000 patients (see <a href="#section-6">CONTRAINDICATIONS</a> and <a href="#section-7">WARNINGS</a>).</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal 
<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, and 
<span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> have been reported in 1 to 5 of 1,000 patients.</p>
<p><span class="Bold">Miscellaneous:</span> Each of the following has been 
reported in 1 to 5 of 1,000 patients: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, eyes, 
or skin; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> or decreased libido; <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; slurred 
speech; <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>; <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Reversible 
<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> has been reported infrequently.</p>
<p>The following adverse reactions have been reported in patients taking nadolol 
and/or other beta-adrenergic blocking agents, but no causal relationship to 
nadolol has been established.</p>
<p><span class="Bold">Central Nervous System:</span> Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> 
progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; an acute 
reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, 
short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> with slightly clouded sensorium, and 
decreased performance on neuropsychometrics.</p>
<p><span class="Bold">Gastrointestinal:</span> Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>; 
<span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; elevated liver enzymes.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; thrombocytopenic or 
nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>; 
<span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>; <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
<p><span class="Bold">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">Pemphigoid</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; hypertensive reaction 
in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>; <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>; Peyronie's disease.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol 
has not been reported with nadolol.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Nadolol can be removed from the general circulation by 
hemodialysis.</p>
<p>In addition to gastric lavage, the following measures should be employed, as 
appropriate. In determining the duration of corrective therapy, note must be 
taken of the long duration of the effect of nadolol.</p>
<a href="http://"></a><a href="http://"></a>Excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span><p>Administer atropine (0.25 to 1.0 mg). If there is no response to 
vagal blockade, administer isoproterenol cautiously.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span><p>Administer a digitalis glycoside and diuretic. It has been 
reported that glucagon may also be useful in this situation.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><p>Administer vasopressors, e.g., epinephrine or levarterenol. 
(There is evidence that epinephrine may be the drug of choice.)</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span><p>Administer a beta<span class="Sub">2</span>-stimulating agent 
and/or a theophylline derivative.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED. NADOLOL MAY BE ADMINISTERED 
WITHOUT REGARD TO MEALS.</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span><p>The usual initial dose is 40 mg nadolol once daily. Dosage may be 
gradually increased in 40 to 80 mg increments at 3 to 7 day intervals until 
optimum clinical response is obtained or there is pronounced slowing of the 
heart rate. The usual maintenance dose is 40 or 80 mg administered once daily. 
Doses up to 160 or 240 mg administered once daily may be needed.</p>
<p>The usefulness and safety in <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> of dosages exceeding 240 mg per 
day have not been established. If treatment is to be discontinued, reduce the 
dosage gradually over a period of 1 to 2 weeks (see <a href="#section-7">WARNINGS</a>).</p>
<a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><p>The usual initial dose is 40 mg nadolol once daily, whether it is 
used alone or in addition to diuretic therapy. Dosage may be gradually increased 
in 40 to 80 mg increments until optimum blood pressure reduction is achieved. 
The usual maintenance dose is 40 or 80 mg administered once daily. Doses up to 
240 or 320 mg administered once daily may be needed.</p>
<a href="http://"></a><a href="http://"></a>Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span><p>Absorbed nadolol is excreted principally by the kidneys and, 
although nonrenal elimination does occur, dosage adjustments are necessary in 
patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The following dose intervals are 
recommended:</p>
<a name="ib6294fd7-0232-4cf5-89bb-818a5b98821e"></a><table width="40%">
<col align="center" width="50%">
<col align="center" width="50%">
<thead><tr class="First Last">
<th align="center">Creatinine<br>Clearance<br>(mL/min/1.73<span class="Sup">2</span>)</th>
<th align="center">Dosage<br>Interval<br>(hours)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">Greater Than 50</td>
<td align="center">24</td>
</tr>
<tr>
<td align="center">31 to 50</td>
<td align="center">24 to 36</td>
</tr>
<tr>
<td align="center">10 to 30</td>
<td align="center">24 to 48</td>
</tr>
<tr class="Last">
<td align="center">Less Than 10</td>
<td align="center">40 to 60</td>
</tr>
</tbody>
</table>
<a href="http://"></a>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nadolol Tablets, USP are available containing 20 mg, 40 mg or 80 
mg of nadolol, USP.</p>
<p>The 20 mg tablets are yellow, round, scored tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">28</span> below the 
score on one side of the tablet and blank on the other side. They are available 
as follows:</p>
<a name="i69836641-43c4-4e58-823e-ddc8b43d6d32"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5295-1<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5295-0</td>
</tr>
</tbody></table>
<br><p>The 40 mg tablets are yellow, round, scored tablets debossed with <span class="Bold">M</span> above the score and <span class="Bold">171</span> below the 
score on one side of the tablet and blank on the other side. They are available 
as follows:</p>
<a name="i63475b35-e77d-416e-8998-1e6fc615f0a6"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 10<br>
</td>
<td>NDC 54868-3257-4<br>
</td>
</tr>
<tr>
<td>Bottles of 30<br>
</td>
<td>NDC 54868-3257-2<br>
</td>
</tr>
<tr>
<td>Bottles of 90<br>
</td>
<td>NDC 54868-3257-6<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 100<br>
</td>
<td>NDC 54868-3257-1</td>
</tr>
</tbody></table>
<br><br><p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for 
Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a 
child-resistant closure.</p>
<a href="#section-"></a><a href="#section-"></a><p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REV OCTOBER 2006<br>NAD:R9</p>
<br><p><br></p>
<p><span class="Bold">Distributed and Repackaged by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Nadolol Tablets, USP  20 mg</p>
<p><img alt="Image of Nadolol 20 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d208918b-a356-4924-91d9-9593981fe0a6&amp;name=Nadolol%2020%20mg%20package%20label.jpg"></p>
<p>Nadolol Tablets, USP  40 mg</p>
<p><img alt="image of Nadolol 40 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d208918b-a356-4924-91d9-9593981fe0a6&amp;name=Nadolol%2040%20mg%20package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NADOLOL 		
					</strong><br><span class="contentTableReg">nadolol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5295(NDC:0378-0028)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NADOLOL</strong> (NADOLOL) </td>
<td class="formItem">NADOLOL</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;28</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5295-0</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5295-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074172</td>
<td class="formItem">05/16/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NADOLOL 		
					</strong><br><span class="contentTableReg">nadolol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3257(NDC:0378-1171)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NADOLOL</strong> (NADOLOL) </td>
<td class="formItem">NADOLOL</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;171</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3257-1</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3257-2</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-3257-4</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-3257-6</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074172</td>
<td class="formItem">01/14/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NADOLOL 		
					</strong><br><span class="contentTableReg">nadolol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3721(NDC:0378-1132)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NADOLOL</strong> (NADOLOL) </td>
<td class="formItem">NADOLOL</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;132</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3721-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3721-2</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074172</td>
<td class="formItem">08/13/2004</td>
<td class="formItem">06/30/2010</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-3721, 54868-5295, 54868-3257), repack(54868-3721, 54868-5295, 54868-3257)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8b910c5e-691b-492d-95df-bb01fd6b0c4f</div>
<div>Set id: d208918b-a356-4924-91d9-9593981fe0a6</div>
<div>Version: 4</div>
<div>Effective Time: 20121001</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
